PA
SCNI

Perennial Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

Perennial Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5
Closed -$11K – 178
2020
Q2 		$11K Buy
+5
New +$8.05K ﹤0.01% 187

Other funds holding SCNI

II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Perennial Advisors's SCNI Position: Q3 2020 in Review

Perennial Advisors sold out of Scinai Immunotherapeutics (SCNI) in Q3 2020, closing a stake of 5 shares — an estimated $11K sold.

Perennial Advisors first reported a position in SCNI in Q2 2020 and held it in 1 quarter. The position peaked at $11K in Q2 2020. 17 funds tracked by Wall St. Rank hold SCNI as of Q3 2020.

  • Perennial Advisors reported no remaining Scinai Immunotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Perennial Advisors sold 5 Scinai Immunotherapeutics shares in Q3 2020, an estimated $11K.
  • Perennial Advisors first reported a position in Scinai Immunotherapeutics in Q2 2020 and held it in 1 quarter.
  • Perennial Advisors's Scinai Immunotherapeutics position peaked at $11K in Q2 2020.
  • 17 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2020.

Based on Perennial Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.